ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer (NMIBC)Serum Institute of India (SII) will manufacture both standard BCG (“sBCG”) and next-generation recombinant BCG (“iBCG”), creating a long-term solution to chronic BCG supply shortage issuesStandard BCG (sBCG) from the Serum Institute is currently administered in number of countries worldwide for treatment of NMIBCRecombinant BCG (iBCG) has demonstrated potent immunogenicity with CD8+ and CD4+ stimulation and improved safety compared to standard BCG in clinical trials across Europe.Collaboration will help to ensure availability of BCG for all approved indications that benefit from ANKTIVA’s triangle offense of natural killer cells, T cells, and memory T cellsGlobal clinical trials planned to study standard of care ANKTIVA plus BCG with globally available sBCG and iBCG from Serum Institute, the QUILT BCG
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®Business Wire
- ImmunityBio partners with Serum Institute for BCG vaccines [Yahoo! Finance]Yahoo! Finance
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 5/9/24 - Form 10-Q
- 5/3/24 - Form EFFECT
- 4/29/24 - Form DEFA14A
- IBRX's page on the SEC website